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Profiling the nucleobase and structure selectivity of anticancer 
drugs and other DNA alkylating agents by RNA sequencing 
Basilius Sauter,[a] and Dennis Gillingham*[a]
Abstract: Drugs that covalently modify DNA are components of most 
chemotherapy regimens, often serving as first-line treatments. 
Classically, the reactivity and selectivity of DNA alkylating agents has 
been determined in vitro with short oligonucleotides. A statistically 
sound analysis of sequence preferences of alkylating agents is 
untenable with serial analysis methods because of the combinatorial 
explosion of sequence possibilities. Next-generation sequencing 
(NGS) is ideally suited for the broad characterization of sequence or 
structure selectivities because it analyzes many sequences at once. 
Herein, we use NGS to report on the chemoselectivity of alkylating 
agents on RNA and apply this technology to the previously 
uncharacterized alkylating agent trimethylsilyl diazomethane. 
DNA alkylating agents are extremely toxic molecules, and yet they 
remain a cornerstone of chemotherapy.[1] In glioblastoma 
multiforme, for example, the alkylating agent temozolomide 
(TMZ)[2] is the only approved drug. One of the world’s first 
anticancer agents was a sulfur mustard,[3] but many other DNA 
alkylating molecules[4] have been discovered either by sifting 
through natural products that bear electrophiles, or by focused 
medicinal chemistry efforts on electrophilic scaffolds with a known 
predilection for nucleic acid modification.[5] While alkylating DNA 
to cause apoptosis is their main mode of action, these alkylating 
agents are indiscriminately reactive, leading to many side effects. 
One of the off-target substrates is the more abundant RNA, but 
whether this contributes to toxicity is unknown. Damage to mRNA 
is mostly short-lived but can lead to longer-lasting effects if they 
cause errors during translation,[6] or if the damage causes a 
catalytic gain-of-function.[6e] With these findings and the discovery 
of RNA repair proteins,[7] the significance of RNA damage needs 
to be re-evaluated.[6a, 6b, 8] Since all of the alkylating drugs on the 
market were discovered before the advent of next generation 
sequencing (NGS), studies of their chemical reactivity on nucleic 
acids were necessarily serial, limiting analyses to a small set of 
synthetic oligodeoxynucleotides or to low-throughput biochemical 
assays such as ligation-mediated PCR.[9] Nucleobase selectivity 
was typically characterized by reactions with mononucleotides, 
which cannot report on sequence context or structure specificity. 
NGS would offer a more nuanced and statistically powerful 
profiling of alkylating agents, but this has gone largely untested. 
A couple of recent NGS approaches that look at sites of cisplatin 
reactivity[10] in both DNA and RNA are the lone exceptions. Other 
reports have looked at whether there might be natural or designed 
RNA aptamer sequences that can predispose an RNA to 
alkylation by organic electrophiles.[11] How natural post-
transcriptional modifications influence sequencing datasets has 
recently been explored.[12] The techniques most similar in 
workflow to what we describe here are SHAPE sequencing and 
other types of high-throughput chemical RNA probing.[13] 
Whereas, however, chemical probing looks at characterizing RNA 
secondary structure or protein binding sites, we hope to offer a 
profile of the chemicals themselves: the types of bases they react 
with and in what ratios, as well as whether they prefer specific 
consensus sequences or specific types of structures. 
 
 
Figure 1. Profiling the selectivity of nucleic acid damaging agents by RNA 
sequencing 
To develop the protocol, we choose to characterize two known 
drugs that operate by a similar mechanism and have a well-
established chemical reactivity profile in DNA. TMZ[2b] and 
streptozotocin (SZ) (see Figure 1B for structures)[14] are both 
purported to generate methyldiazonium upon nucleophilic 
activation and this powerful electrophile[15] then preferentially 
targets G, modifying both its N7 and O6 positions.[16] After 
establishing the protocol with these two molecules, we 
implemented the method to profile the reactivity of 
trimethylsilyldiazomethane (TMS-DAM) and dimethylsulfate 
(DMS). The reactivity of TMS-DAM with DNA and RNA is 
unstudied, but in principle should show similar reactivity as TMZ 
and SZ since it also generates a methyldiazonium in protic 
solvents.[17] DMS, on the other hand, is frequently used as a 
reagent in chemical RNA probing and in fact was one of the key 
reagents for the original Maxam-Gilbert sequencing.[18] Indeed, 
our sequencing data jibes with the observed chemical reactivity 
profile in Maxam-Gilbert sequencing. The advantage of NGS is 
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that new alkylating agents with unknown reactivity can be quickly 
profiled across a broad set of sequences in a single experiment. 
We started by developing the sequencing method and data 
analysis pipeline to identify sites of alkylation. Over the past few 
years classical RNA chemical profiling methods have been 
adapted for whole transcriptome NGS.[13] Data analysis 
approaches vary, but the basic concept in these techniques is the 
same: RNAs are chemically modified and then reverse 
transcribed (RT) to complementary DNAs (cDNAs). The 
chemically modified positions prematurely halt RT or cause 
mutations during read-through; modifications in the original RNA 
can then be inferred from premature stops or mutations in the 
sequencing reads. While these techniques were developed to 
study epigenetics and RNA structure, our goal was to adapt them 
for broad characterization of the chemo- and site-selectivity of 
nucleic acid alkylating agents. 
 
Figure 2. Sequencing library preparation protocol for profiling RNA damage 
selectivity. 
Our protocol is similar to those used in previous reports in RNA 
structure based profiling,[13] but most closely resembles the Mod-
Seq protocol reported by the McManus lab.[13c] The biggest 
changes we’ve made to the McManus protocol are that we use 
STAR[19] for genome alignment and that we use an alkaline 
fragmentation protocol (more on this below). In brief, we began by 
treating HeLa cells or HeLa whole transcriptome isolates with a 
variety of alkylating agents at high concentration (Figure 2, step 
1). The resulting RNA pools were then fragmented, and adaptors 
were ligated at both ends (step 2). The 3’ adaptor is a universal 
PCR primer, while the 5’ adaptor is meant to serve as a stop-
marker downstream in the bioinformatics analysis. An enrichment 
step with magnetic beads bearing a complement to the 5’ adaptor 
insures that only successful ligation products proceed to the next 
step. RT then creates cDNAs of two types; RTs that stop 
prematurely will give cDNAs that lack a complement to the 
originally ligated 5’ stop-marker, while those that copy normally 
will have this sequence at their 3’ ends. The cDNAs are then 
circularized and the sequences that bear the stop-marker adaptor 
are removed by a magnetic bead negative selection (the beads 
contain an oligonucleotide complementary to the cDNA stop 
marker). The remaining cDNAs are then PCR amplified with 
primers that bear the Illumina sequences, purified with AMPure 
beads to minimize empty primer reads and then submitted for 
NGS sequencing. 
As already mentioned, the biggest difference between our 
method and SHAPE sequencing is that we use alkaline 
fragmentation. Although ZnCl2 fragmentation was also an 
option,[13d] we opted for the alkaline method for chemical profiling 
since it reports on total modification (since N7G alkylations are 
depurinated under alkaline conditions and hence turn up as stops 
in the data), while the ZnCl2 method (which does not efficiently 
depurinate) reports more on the modifications in the Watson-Crick 
face. Before doing any data filtering we first wanted to analyze 
whether the drug treated samples showed any consistent 
changes in stop positions across all stops. Indeed, in the treated 
samples we saw a substantial increase in the number of stops at 
guanine residues. We then reanalyzed the stops after applying a 
significance test filtering (Cochran-Mantel-Haenszel testing 
according to the method previously described).[13c] We first 
analyzed the stop-signal for the four alkylating agents shown in 
Figure 1B both in vitro and in live cells. For all but DMS this is the 
first time that these DNA alkylating agents have been 
characterized with NGS. As expected, they all showed a 
preference for guanine alkylation (signals are determined by 
comparison with matched DMSO controls). None of these 
purportedly unspecific alkylating agents show a sequence logo 
preference (see the ESI), consistent with their generating a potent 
but unselective alkylating agent. The alkylating profiles in live cells 
match closely those seen with transcriptome isolates except for 
TMZ. TMZ demonstrated extremely poor solubility in the culture 
medium, we believe this leads to a low effective treatment 
concentration and hence the stop-signals with TMZ are 
indistinguishable from the untreated controls. We also 
independently measured each base’s propensity for RNA 
alkylation with DMS by reacting the monoribonucleotides with 
DMS and then examining the product ratios by UPLC-MS; this 
method gives conversions of 86, 12, 6, and 0 for G, A, C, and U 
respectively (see ESI figure S11 for data), exactly as the reactivity 
order predicted by sequencing based profiling in vitro (see DMS 
signals in panels B of Figure 3). These profiles are also consistent 
with earlier work on DNA modification[16, 20] with DMS, which 
suggests that the order of reactivity should be G>A>C>T in an 
approximately 78:20:2:0 ratio. 
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Figure 3. (A) Crude sequencing data indicates a significant preference for 
guanine stops in comparison to untreated controls; (B) Applying the profiling 
sequencing workflow on the in vitro data delivers stops that show a strong 
preference for G; (C) Alkylation reactions in cell culture analysed by the 
chemical profiling method show consistent profiles except TMZ, which is highly 
insoluble in the culture medium (note: analyses in B and C excluded ribosomal 
RNA (rRNA) since they are the most populous and any selectivity inherent to 
rRNA would therefore dominate the data).  
 
In structural probing tertiary structures are approximated by 
calculating a reactivity of each nucleobase position.10d In Figure 4 
we focus on the 18S rRNA to examine in detail structural 
specificities of alkylation. In Figure 4A we see that TMS-DAM 
would be a poor structural probing reagent because it can target 
both double and single-stranded regions. On the other hand, if we 
look at the A and C stops for DMS, we see a strong preference 
for single stranded regions, a feature that makes DMS an 
excellent chemical probing reagent. The more broad reactivity of 
TMS-DAM, however, could be more advantageous for probing 
intermolecular interactions. Indeed if we look at the live cell results 
for both TMS-DAM and DMS we see that modification at double-
stranded regions is completely lost. Taken together, these 
analyses validate that NGS is an effective way to profile the 
structural selectivity of DNA and RNA damaging agents. As 
shown in Figure 4B, only guanine is alkylated in double-stranded 
regions in 18S rRNA in the live cell experiments. This unexpected 
observation could stem from several factors; the most interesting 
would be that this reactivity difference is reporting on tertiary or 
quaternary interactions of the 18S rRNA.  Going forward we would 
like to increase sequencing depths so that we can search for 
putative sites of intermolecular interactions with statistical 
confidence, and then compare putative interactions with other 
recently described probing methods.[13f, 21]  
 
Figure 4. Selectivity of alkylation for different structural motifs in 18s rRNA in 
vitro (A) and in live cells (B).  
A disadvantage of the technique is that it is blind to 
modifications that cause neither RT stops nor frequent mutations. 
TMS-DAM offers an example of this shortcoming. Alkylation 
reactions with diazo electrophiles require a free proton to activate 
the diazo to a highly electrophilic diazonium.[22] Guanine and 
uracil have similar pKas and they are the first ionisable protons in 
oligoribonucleotides,[23] which should give them similar reactivity 
with TMS-DAM. We tested the reactivity of all four RNA bases 
with TMS-DAM as mononucleosides or in HeLa total 
transcriptome RNA (Figure 5A). In both cases the major product 
was the m3U alkylation product followed by m6G and m1G. The 
Kool lab has recently shown that m3U is relatively well-tolerated 
during RT, making it difficult to detect in NGS datasets.[12] Our 
data is consistent with this conclusion since although there is 
substantial uridine modification according to chemical analysis, 
the NGS data show predominately guanine alkylation. With this in 
mind, a protocol for characterizing new alkylating agents would 
be to examine the in vitro specificity in mononucleotides and then 
use NGS to look for sequence or structural selectivity across 
many different sequences. 
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Figure 5. A. Alkylation reactions with TMS-DAM were carried out on both 
monoribonucleosides and total HeLa RNA. In the case of total RNA a digestion 
was carried out to generate monoribonucleosides for analysis; the bar graph 
shows the relative reactivity of each base; B. Crude HPLC traces show that A 
and C are not modified, while G gives two products (m1G and m6G) and U gives 
a single product (m3U). 
We’ve shown that RNA sequencing can be used to chemically 
profile alkylating anti-cancer agents or any other molecule that 
can covalently modify RNA and gives RT stops or mutations 
during cDNA synthesis. To develop the method, we first chose 
electrophiles with a well-established reactivity profile in DNA, and 
then profiled a substrate that has never been analysed in RNA 
alkylation (TMS-DAM) to show how the technique could be used 
in practice. To get a high enough signal-to-noise ratio, we needed 
to use high drug concentration. While this is an effective strategy 
for chemical profiling and RNA probing, it might obscure valuable 
additional information such as whether there are any sequence or 
transcript preferences. In the future we will include an enrichment 
step in reactions with modified electrophiles, allowing us to use 
reduce drug concentrations to levels that would not oversaturate 
any inherent drug selectivity and will help us identify whether 
alkylating drugs damage specific transcripts or consensus 
sequences. Already in its present form, however, the technique is 
an efficient way to profile the nucleobase and tertiary structural 
selectivity of DNA and RNA damaging agents. 
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